ReviewBritish journal of cancer2008
EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality.
Review in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis.Drugs in R&D · 2011Pooled it
- Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Pyrazole and Pyrazoline-Based EGFR TK Inhibitors: A Review Study Emphasizing Structure-Activity Relationship (SAR).Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Review
- Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations.Frontiers in immunology · 2025Review
- Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Article
- EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.Journal of experimental & clinical cancer research : CR · 2015Article
- Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis.Oncology letters · 2013Article
- Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.Investigational new drugs · 2012Article
- Ultraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor.The Journal of biological chemistry · 2011Article
- Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.Translational oncology · 2011Article
- Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.Cancer science · 2009Article
- Antibodies specifically targeting a locally misfolded region of tumor associated EGFR.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Activated epidermal growth factor receptor in ovarian cancer.Cancer treatment and research · 2009Review
- Treatment of pediatric brain tumors.Journal of cellular physiology · 2008Review
- Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical experience recently reported with epidermal growth factor receptor (EGFR)-targeting drugs confirms the synergistic interactions observed between these compounds and conventional cytotoxic agents, which were previously established at the preclinical stage. There are, however, examples of major gaps between the bench and the bedside. Particularly demonstrative is the failure of the tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) combined with chemotherapy in pretreated nonsmall cell lung cancer patients. These discrepancies can be due to several factors such as the methodology used to evaluate TKI plus cytotoxic agent combinations in preclinical models and the insufficient consideration given to the importance of the drug sequences for the tested combinations. Recent advances in understanding the biologic basis of acquired resistance to these agents have great potential to improve their clinical effectiveness. The purpose of this review is to critically examine the experimental conditions of the preclinical background for anti-EGFR drug-cytotoxic agent combinations and to attempt to explain the gap between clinical observations and preclinical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.